NO20085032L - Aminotiazoler og deres anvendelser - Google Patents

Aminotiazoler og deres anvendelser

Info

Publication number
NO20085032L
NO20085032L NO20085032A NO20085032A NO20085032L NO 20085032 L NO20085032 L NO 20085032L NO 20085032 A NO20085032 A NO 20085032A NO 20085032 A NO20085032 A NO 20085032A NO 20085032 L NO20085032 L NO 20085032L
Authority
NO
Norway
Prior art keywords
aminothiazoles
relief
therapy
diseases
useful
Prior art date
Application number
NO20085032A
Other languages
English (en)
Norwegian (no)
Inventor
Matthew J Lamarche
Simon Bushell
Michael A Patane
Lewis Whitehead
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20085032(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20085032L publication Critical patent/NO20085032L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NO20085032A 2006-05-31 2008-12-02 Aminotiazoler og deres anvendelser NO20085032L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80969306P 2006-05-31 2006-05-31
PCT/US2007/012768 WO2007142986A2 (en) 2006-05-31 2007-05-30 Aminothiazole derivatives and their uses as antibacterial agents

Publications (1)

Publication Number Publication Date
NO20085032L true NO20085032L (no) 2008-12-16

Family

ID=38645676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085032A NO20085032L (no) 2006-05-31 2008-12-02 Aminotiazoler og deres anvendelser

Country Status (31)

Country Link
US (2) US7851439B2 (es)
EP (2) EP2044101B1 (es)
JP (1) JP5351014B2 (es)
KR (1) KR101061658B1 (es)
CN (2) CN102399260B (es)
AR (1) AR060977A1 (es)
AU (1) AU2007255025B2 (es)
BR (1) BRPI0711885A2 (es)
CA (1) CA2650133A1 (es)
CL (1) CL2007001542A1 (es)
CR (1) CR10430A (es)
DK (1) DK2044101T3 (es)
EC (1) ECSP088922A (es)
ES (1) ES2441993T3 (es)
HR (1) HRP20140055T1 (es)
IL (1) IL194880A (es)
MA (1) MA30485B1 (es)
MX (1) MX2008015216A (es)
MY (1) MY146920A (es)
NO (1) NO20085032L (es)
NZ (1) NZ572154A (es)
PE (2) PE20121011A1 (es)
PL (1) PL2044101T3 (es)
PT (1) PT2044101E (es)
RU (1) RU2450015C2 (es)
SI (1) SI2044101T1 (es)
TN (1) TNSN08496A1 (es)
TW (2) TWI342310B (es)
UA (1) UA95627C2 (es)
WO (1) WO2007142986A2 (es)
ZA (1) ZA200808449B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060977A1 (es) 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
EA200900816A1 (ru) 2006-12-20 2009-12-30 Новартис Аг Антибактериальные соединения и способы их получения
AU2008258639B2 (en) 2007-06-04 2012-07-05 Novartis Ag Macrocycles and their uses
AU2012261611B2 (en) * 2007-12-12 2014-05-15 Novartis Ag Aminothiazoles and their uses
PE20091108A1 (es) * 2007-12-12 2009-08-24 Novartis Ag Aminotiazoles y sus usos
WO2014167371A1 (en) * 2013-04-12 2014-10-16 Naicons S.C.A.R.L. Analogs of the antibiotic aminothiazole ge2270
CN106366168B (zh) * 2016-08-26 2020-09-15 上海交通大学 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN113219078B (zh) * 2021-03-25 2022-12-16 广东产品质量监督检验研究院(国家质量技术监督局广州电气安全检验所、广东省试验认证研究院、华安实验室) 一种生活用纸制品中17种有机抗菌剂快速筛查方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202241A (en) 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
EP0406745B1 (en) 1989-07-04 1995-01-25 GRUPPO LEPETIT S.p.A. Antibiotic GE 2270 factors A1, A2, A3 and H
DK0451486T3 (da) 1990-03-08 1995-05-08 Lepetit Spa Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T
IL100572A (en) * 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
EP0529410B1 (en) 1991-08-30 1998-02-25 Biosearch Italia S.p.A. Antibiotic GE 2270 factor C2a
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
JPH08504782A (ja) 1992-12-22 1996-05-21 グルポ・レペチツト・エス・ピー・エイ 抗生物質ge37468a、b及びc
EP0791069A1 (en) * 1994-11-08 1997-08-27 Biosearch Italia S.p.A. Microbial transformation process for obtaining antibiotic ge 2270 factor d 2?
SI0801655T1 (en) 1995-02-07 1998-08-31 Biosearch Italia S.P.A. Basic proline-amide derivatives of ge 2270 and ge 2270-like antibiotics
JP3518606B2 (ja) 1995-02-07 2004-04-12 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ Ge2270及びge2270−様抗生物質の塩基性オキサゾリン−アミド誘導体
JP2000505438A (ja) * 1996-02-14 2000-05-09 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ 抗生物質GE2270因子C▲下2a▼、D▲下2▼およびEの誘導体
JPH1059997A (ja) * 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
WO2003105881A1 (en) * 2002-06-17 2003-12-24 Vicuron Pharmaceuticals Inc. Use of amide derivative of ge 2270 factor a3 for the treatment of acne
WO2006086012A2 (en) 2004-09-22 2006-08-17 Merck & Co., Inc. Antibiotic compound
AR060977A1 (es) * 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
PE20091108A1 (es) * 2007-12-12 2009-08-24 Novartis Ag Aminotiazoles y sus usos

Also Published As

Publication number Publication date
CN102399260A (zh) 2012-04-04
JP2009538914A (ja) 2009-11-12
IL194880A0 (en) 2011-08-01
EP2322536A2 (en) 2011-05-18
EP2044101A2 (en) 2009-04-08
CA2650133A1 (en) 2007-12-13
MA30485B1 (fr) 2009-06-01
TW201107337A (en) 2011-03-01
HRP20140055T1 (hr) 2014-02-14
WO2007142986A3 (en) 2008-04-10
ZA200808449B (en) 2014-12-23
RU2450015C2 (ru) 2012-05-10
MX2008015216A (es) 2008-12-12
CL2007001542A1 (es) 2008-03-14
WO2007142986A2 (en) 2007-12-13
PE20121011A1 (es) 2012-08-25
EP2044101B1 (en) 2013-10-09
DK2044101T3 (da) 2014-01-13
UA95627C2 (ru) 2011-08-25
HK1127614A1 (en) 2009-10-02
PT2044101E (pt) 2014-01-03
TW200811189A (en) 2008-03-01
IL194880A (en) 2015-02-26
AU2007255025B2 (en) 2011-07-14
KR101061658B1 (ko) 2011-09-01
TWI342310B (en) 2011-05-21
US7851439B2 (en) 2010-12-14
US20080221142A1 (en) 2008-09-11
ECSP088922A (es) 2008-12-30
CR10430A (es) 2009-01-15
RU2008150785A (ru) 2010-07-10
SI2044101T1 (sl) 2014-01-31
JP5351014B2 (ja) 2013-11-27
TNSN08496A1 (en) 2010-04-14
PE20080103A1 (es) 2008-04-03
US20100267757A1 (en) 2010-10-21
CN102399260B (zh) 2015-04-15
EP2322536A3 (en) 2011-11-30
AR060977A1 (es) 2008-07-23
AU2007255025A1 (en) 2007-12-13
NZ572154A (en) 2011-12-22
KR20090006869A (ko) 2009-01-15
BRPI0711885A2 (pt) 2012-03-06
ES2441993T3 (es) 2014-02-07
MY146920A (en) 2012-10-15
PL2044101T3 (pl) 2014-03-31
CN101454337A (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
NO20084749L (no) Organiske forbindelser og deres anvendelser
NO20085032L (no) Aminotiazoler og deres anvendelser
NO20082753L (no) Transdermalt terapeutisk system
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
CR10433A (es) Compuestos organicos y sus usos
NO20081042L (no) PPAR aktive forbindelser
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
MX2010006203A (es) Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina.
WO2009031040A3 (en) Compounds with anti-cancer activity
NO20090880L (no) Banumsulfatinneholdende kompositt
DK1888595T3 (da) Spiro-oxindolforbindelser og deres anvendelser som terapeutiske midler
NO20081838L (no) 5-lipoksygenaseaktiverende protein-(FLAP)-inhibitorer
BRPI0817871A2 (pt) Aparelho para controle de fluxo em um órgão do corpo.
ATE526375T1 (de) Korrosionshemmende beschichtungszusammensetzung auf basis waesseriger dispersionen, umfassend ein organisches titanat und/oder zirkonat
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
NO20084850L (no) MGLUR5 modulatorer I
EA201101477A1 (ru) Органические соединения и их применение
NO20085029L (no) Substituerte pyridylamidforbindelser som modulatorer av histamin H3 reseptoren
DK2041069T3 (da) Benzylaminer, fremgangsmåde til fremstilling deraf og deres anvendelse som anti-inflammatoriske midler
BRPI0816952A2 (pt) Composição para tratar ou contralar uma infecção em um indivíduo, e, usos de uma fluoroquinolona e de uma combinação
NO20100268L (no) Anvendelse av gjaercellevegger til behandling og/eller forebygging av hyperinsulinemi
WO2008051523A3 (en) Carbazole derivatives useful as medicaments in cancer therapy